KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Equity Investments: 2009-2011

Historic Gains from Equity Investments for Biomarin Pharmaceutical (BMRN) over the last 1 years, with Mar 2011 value amounting to $542,000.

  • Biomarin Pharmaceutical's Gains from Equity Investments fell 21.56% to $542,000 in Q1 2011 from the same period last year, while for Mar 2011 it was $2.8 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2010, which is 15.30% up from last year.
  • According to the latest figures from Q1 2011, Biomarin Pharmaceutical's Gains from Equity Investments is $542,000, which was down 31.91% from $796,000 recorded in Q4 2010.
  • In the past 5 years, Biomarin Pharmaceutical's Gains from Equity Investments registered a high of $864,000 during Q2 2010, and its lowest value of $542,000 during Q1 2011.
  • Moreover, its 3-year median value for Gains from Equity Investments was $691,000 (2010), whereas its average is $719,143.
  • Data for Biomarin Pharmaceutical's Gains from Equity Investments shows a maximum YoY declined of 21.56% (in 2011) over the last 5 years.
  • Over the past 3 years, Biomarin Pharmaceutical's Gains from Equity Investments (Quarterly) stood at $821,000 in 2009, then fell by 3.05% to $796,000 in 2010, then declined by 21.56% to $542,000 in 2011.
  • Its Gains from Equity Investments stands at $542,000 for Q1 2011, versus $796,000 for Q4 2010 and $640,000 for Q3 2010.